News
Debunking Myths of Migraine’s Role in Dementia: Olivia Begasse de Dhaem, MD, FAHS
September 6th 2023The headache specialist at Hartford Healthcare Headache Center emphasized the importance of avoiding unnecessary fear surrounding the potential link between migraine and dementia, as current evidence does not strongly support it being a significant risk factor. [WATCH TIME: 2 minutes]
The Ever-Changing Management of Dyskinesia in Parkinson Disease
September 5th 2023An expert panel discusses diagnosis and treatment of patients with Parkinson disease, exploring the challenges in managing dyskinesia, finding a balance between OFF episodes and ON time, and current and emerging treatment options.
Neurobiological Insights Into Gait and Balance Control in Parkinson Disease
September 5th 2023Nicolaas Bohnen, MD, PhD, professor of radiology and neurology at the University of Michigan, discussed the main takeaways from his keynote lecture on posture and gait in Parkinson disease presented at the 2023 MDS Congress.
Restoring Dystrophin Protein Production in DMD With Exon Skipping AOC Therapy: Steve Hughes, MD
September 5th 2023The chief medical officer at Avidity Biosciences talked about how its exon skipping AOC therapies are designed to address the lack of functional dystrophin protein among patients with Duchenne muscular dystrophy to improve muscle function. [WATCH TIME: 4 minutes]
Phase 3 KINECT-4 Findings Show Valbenazine Decreases Tardive Dyskinesia Severity
September 4th 2023On average, clinician-rated TD severity, measured by AIMS, and patient-reported assessment of the physical, social and emotional impact of TD, measured by TDIS, decreased with one-capsule, once-daily valbenazine over 48 weeks.
ALS Agent CNM-Au8 Displays Survival Benefit and Delay of Clinical Worsening in 2 Year Follow-Up
September 2nd 2023Findings from an open-label extension trial among 45 patients with ALS showed a significant median survival benefit of 19.3 months and a significant 52% decreased risk of ALS clinical worsening events after treatment.
Levodopa as Initial Parkinson Treatment Shows Best Long-Term Prognostic Outcome for Quality of Life
September 1st 2023When compared with levodopa-sparing agents, treatment levodopa alone resulted in significantly better patient-rated Parkinson’s Disease Questionnaire activities of daily living and summary index scores.
Machine Learning Algorithm Accurately Diagnoses Parkinsonian Syndromes, Study Shows
September 1st 2023Parkinsonian syndromes, including multiple systems atrophy and progressive supranuclear palsy, have similar symptoms to Parkinson disease but are more distinct and each have corresponding therapies that are available for them.
Addressing Misdiagnosis and Delayed Diagnosis in Multiple Sclerosis: Andrew Solomon, MD
September 1st 2023The associate professor of neurological sciences at the University of Vermont in Burlington discussed the persistent issue of delayed and misdiagnoses among patients with multiple sclerosis, highlighting the need to improve accurate diagnosis. [WATCH TIME: 3 minutes]
Research Identifies Novel Genetic Risk Factor of Parkinson Disease in African Populations
September 1st 2023Findings of a new novel genetic risk factor could inform future GBA1 clinical trials, improving patient stratification and the odds of designing trials that are more likely to produce meaningful and actionable answers.
Creating Efficient, Well-Rounded Neurology Departments
August 31st 2023A panel of former AUPN presidents detailed how advances in neurology have changed the way the clinical specialty is taught, and why collaboration among leadership remains vital to creating an effective neurology department. [WATCH TIME: 7 minutes]
Duchenne Agent Pamrevlumab Fails to Meet Primary End Point in Phase 3 LELANTOS-2 Trial
August 31st 2023Despite pamrevlumab being generally safe and well tolerated, the potential first-in-class connective tissue growth factor inhibitor antibody did not meet its primary endpoint in a phase 3 trial for ambulator Duchenne muscular dystrophy.
Revolutionizing Dementia Research With Synuclein Biomarker Tests
August 31st 2023Russell Lebovitz, MD, PhD, chief executive officer and cofounder of Amprion, discussed the ongoing collaboration focused on exploring the role of misfolded synuclein traditionally associated with Parkinson disease and in various forms of dementia.
The Road Ahead for BTK Inhibitors in Multiple Sclerosis: Amit Bar-Or, MD, FRCPC, FAAN, FANA
August 31st 2023The Melissa and Paul Anderson President’s Distinguished Professor of Neurology, Perelman School of Medicine, University of Pennsylvania, talked about the promising potential of BTK inhibitors in treating both relapsing and progressive forms of multiple sclerosis. [WATCH TIME: 6 minutes]
Nusinersen Exhibits Long-Term Safety and Efficacy Across Wide Spectrum of SMA Severity
August 31st 2023Findings from a real-world study among 120 patients with SMA suggests that nusinersen administration is safe and well tolerated, with only 30% of the patients mostly experiencing mild adverse events.
Machine Learning Algorithm Shows Ability to Distinguish Tic From NonTic Movements
August 31st 2023Despite the challenge of distinguishing tics from extra movements, machine learning technology could potentially help researchers with reducing time spent analyzing video recordings of patients with tic disorders.
EXPLORE44's Approach to Rare Disease Treatment for Duchenne Muscular Dystrophy: Steve Hughes, MD
August 30th 2023The chief medical officer at Avidity Biosciences discussed the phase 1/2 EXPLORE44 trial, assessing an investigational treatment for Duchenne muscular dystrophy, and highlighted the potential of the treatment based on the recent FDA orphan drug and fast track designations. [WATCH TIME: 4 minutes]
